Clinical Trial Update: The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of the Mesenchymal Stem Cell product iSCLife-POI for Premature Ovarian Insufficiency has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premature Ovarian Insufficiency

Drugs mentioned

• iSCLife-POI (mesenchymal stem cells)

Snippet

Sponsor: Sclnow Biotechnology Co., Ltd. | Conditions: Premature Ovarian Failure | Phase 2 | Status: SUSPENDED